{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:05:51Z","timestamp":1758931551832,"version":"3.44.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"DOI":"10.1186\/s12981-025-00789-7","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T08:30:42Z","timestamp":1758875442000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes on B\/F\/TAF and dolutegravir-based regimens at 12 months following regimen switch: an observational cohort study"],"prefix":"10.1186","volume":"22","author":[{"given":"Paul E.","family":"Sax","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janna","family":"Radtchenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Dunbar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Guber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neia Prata","family":"Menezes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karam","family":"Mounzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moti","family":"Ramgopal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Elion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"789_CR1","unstructured":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. HHS panel on antiretroviral guidelines for adults and adolescents\u2014a working group of the office of AIDS Research Advisory Council (OARAC). Available at https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK586306\/. Accessed 6 Feb 2025."},{"key":"789_CR2","doi-asserted-by":"publisher","unstructured":"Gandhi RT, Landovitz RJ, Sax PE, et al. Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the international antiviral Society\u2013USA panel. JAMA. 2024;01. https:\/\/doi.org\/10.1001\/jama.2024.24543.","DOI":"10.1001\/jama.2024.24543"},{"issue":"9893","key":"789_CR3","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","volume":"382","author":"P Cahn","year":"2013","unstructured":"Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet Lond Engl. 2013;382(9893):700\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(13)61221-0.","journal-title":"Lancet Lond Engl"},{"issue":"2","key":"789_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/cid\/ciu221","volume":"59","author":"DA Osterholzer","year":"2014","unstructured":"Osterholzer DA, Goldman M. Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection. Clin Infect Dis Off Publ Infect Dis Soc Am. 2014;59(2):265\u201371. https:\/\/doi.org\/10.1093\/cid\/ciu221.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"1","key":"789_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/QAI.0000000000001306","volume":"75","author":"JE Gallant","year":"2017","unstructured":"Gallant JE, Thompson M, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-Day monotherapy in HIV-1-Infected adults. J Acquir Immune Defic Syndr 1999. 2017;75(1):61\u20136. https:\/\/doi.org\/10.1097\/QAI.0000000000001306.","journal-title":"J Acquir Immune Defic Syndr 1999"},{"issue":"6","key":"789_CR6","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","volume":"7","author":"C Orkin","year":"2020","unstructured":"Orkin C, DeJesus E, Sax PE, et al. Fixed-dose combination bictegravir, emtricitabine, and Tenofovir Alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. Lancet HIV. 2020;7(6):e389\u2013400. https:\/\/doi.org\/10.1016\/S2352-3018(20)30099-0.","journal-title":"Lancet HIV"},{"issue":"10107","key":"789_CR7","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","volume":"390","author":"PE Sax","year":"2017","unstructured":"Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and Tenofovir Alafenamide versus dolutegravir with emtricitabine and Tenofovir Alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390(10107):2073\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(17)32340-1.","journal-title":"Lancet"},{"issue":"4","key":"789_CR8","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1016\/S2352-3018(17)30016-4","volume":"4","author":"PE Sax","year":"2017","unstructured":"Sax PE, DeJesus E, Crofoot G, et al. Bictegravir versus dolutegravir, each with emtricitabine and Tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Lancet HIV. 2017;4(4):e154\u201360. https:\/\/doi.org\/10.1016\/S2352-3018(17)30016-4.","journal-title":"Lancet HIV"},{"issue":"10107","key":"789_CR9","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","volume":"390","author":"J Gallant","year":"2017","unstructured":"Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and Tenofovir Alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet Lond Engl. 2017;390(10107):2063\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(17)32299-7.","journal-title":"Lancet Lond Engl"},{"issue":"8","key":"789_CR10","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","volume":"4","author":"J van Wyk","year":"2020","unstructured":"van Wyk J, Ajana F, Bisshop F, De Wit S, Osiyemi O, Portilla Sogorb J, et al. Efficacy and safety of switching to dolutegravir\/lamivudine Fixed-Dose 2-Drug regimen vs continuing a Tenofovir Alafenamide\u2013Based 3- or 4-Drug regimen for maintenance of virologic suppression in adults living 2 with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO 3 study. Clin Infect Dis. 2020;4(8):1920\u20139. https:\/\/doi.org\/10.1093\/cid\/ciz1243.","journal-title":"Clin Infect Dis"},{"key":"789_CR11","doi-asserted-by":"crossref","unstructured":"Llibre JM, Hung CC, Brinson C, Castelli F, Girard PM, Kahl LP et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018;391(10123):839\u201349.","DOI":"10.1016\/S0140-6736(17)33095-7"},{"issue":"7","key":"789_CR12","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1016\/S2352-3018(18)30091-2","volume":"5","author":"ES Daar","year":"2018","unstructured":"Daar ES, DeJesus E, Ruane P, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and Tenofovir Alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e347\u201356. https:\/\/doi.org\/10.1016\/S2352-3018(18)30091-2.","journal-title":"Lancet HIV"},{"issue":"2","key":"789_CR13","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","volume":"73","author":"PE Sax","year":"2021","unstructured":"Sax PE, Rockstroh JK, Luetkemeyer AF, et al. Switching to bictegravir, emtricitabine, and Tenofovir Alafenamide in virologically suppressed adults with human immunodeficiency virus. Clin Infect Dis Off Publ Infect Dis Soc Am. 2021;73(2):e485\u201393. https:\/\/doi.org\/10.1093\/cid\/ciaa988.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"7","key":"789_CR14","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","volume":"5","author":"JM Molina","year":"2018","unstructured":"Molina JM, Ward D, Brar I, et al. Switching to fixed-dose bictegravir, emtricitabine, and Tenofovir Alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e357\u201365. https:\/\/doi.org\/10.1016\/S2352-3018(18)30092-4.","journal-title":"Lancet HIV"},{"key":"789_CR15","doi-asserted-by":"publisher","unstructured":"Sax P, Althoff K, Eron J et al. Impact of adherence on viral suppression with bictegravir and dolutegravir (DTG) containing triple therapy in clinical practice. HIV Glasgow \u2013 Virtual, 5\u20138 October 2020. J Intern AIDS Soc 2020; 23: e25616. https:\/\/doi.org\/10.1002\/jia2.25616. Abstract P029.","DOI":"10.1002\/jia2.25616"},{"issue":"3","key":"789_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/QAI.0000000000002142","volume":"82","author":"KK Byrd","year":"2019","unstructured":"Byrd KK, Hou JG, Hazen R, Kirkham H, Suzuki S, Clay PG, et al. Antiretroviral adherence level necessary for HIV viral suppression using Real-World data. J Acquir Immune Defic Syndr. 2019;82(3):245\u201351.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"789_CR17","doi-asserted-by":"publisher","first-page":"1122018","DOI":"10.3389\/fphar.2023.1122018","volume":"14","author":"MM Milward de Azevedo Meiners","year":"2023","unstructured":"Milward de Azevedo Meiners MM, Ara\u00fajo Cruz I, de Toledo MI. Adherence to antiretroviral therapy and viral suppression: analysis of three periods between 2011 and 2017 at an HIV-AIDS center, Brazil. Front Pharmacol. 2023;14:1122018.","journal-title":"Front Pharmacol"},{"issue":"10","key":"789_CR18","first-page":"1129","volume":"29","author":"M Komandt","year":"2023","unstructured":"Komandt M, Canfield S, Lengel M, Gilmore V, Kilcrease C. Correlation between medication adherence using proportion of days covered and achieving viral suppression in patients living with HIV. J Manag Care Spec Pharm. 2023;29(10):1129\u201337.","journal-title":"J Manag Care Spec Pharm"},{"issue":"10107","key":"789_CR19","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","volume":"390","author":"PE Sax","year":"2017","unstructured":"Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ, Antinori A, et al. Coformulated bictegravir, emtricitabine, and Tenofovir Alafenamide versus dolutegravir with emtricitabine and Tenofovir Alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390(10107):2073\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(17)32340-1. Epub 2017 Aug 31. PMID: 28867499.","journal-title":"Lancet"},{"issue":"1","key":"789_CR20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/jac\/dkae407","volume":"80","author":"K Andreatta","year":"2025","unstructured":"Andreatta K, Sax PE, Wohl D, D\u2019Antoni ML, Liu H, Hindman JT, Callebaut C. Efficacy of bictegravir\/emtricitabine\/tenofovir Alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy. J Antimicrob Chemother. 2025;80(1):281\u201391. https:\/\/doi.org\/10.1093\/jac\/dkae407. PMID: 39556192; PMCID: PMC11695908.","journal-title":"J Antimicrob Chemother"},{"key":"789_CR21","doi-asserted-by":"publisher","unstructured":"Maggiolo F, Valenti MD, BSc D, Teocchi R, BSc CL, Di Filippo MD, Rizzi EMD. M, MD. Real world data on forgiveness to uncomplete adherence to bictegravir\/ emtricitabine\/tenofovir alafenamide. J Int Assoc Provid AIDS Care. 2022;21:23259582221140208. https:\/\/doi.org\/10.1177\/23259582221140208.","DOI":"10.1177\/23259582221140208"},{"issue":"10","key":"789_CR22","doi-asserted-by":"publisher","first-page":"ofae560","DOI":"10.1093\/ofid\/ofae560","volume":"11","author":"C-P Rolle","year":"2024","unstructured":"Rolle C-P, Castano J, Nguyen V, Hinestrosa F, DeJesus E. Efficacy, safety, and tolerability of switching from bictegravir\/emtricitabine\/tenofovir Alafenamide to dolutegravir\/lamivudine among adults with virologically suppressed HIV: the DYAD study. Open Forum Infect Dis. 2024;11(10):ofae560. https:\/\/doi.org\/10.1093\/ofid\/ofae560.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"789_CR23","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/cid\/ciac130","volume":"76","author":"JM Llibre","year":"2023","unstructured":"Llibre JM, Brites C, Cheng C-Y, Osiyemi O, Galera C, Hocqueloux L, et al. Efficacy and safety of switching to the 2-Drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-Drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial. Clin Infect Dis. 2023;76(4):720\u20139. https:\/\/doi.org\/10.1093\/cid\/ciac130.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"789_CR24","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/QAI.0000000000002454","volume":"85","author":"RK Acosta","year":"2020","unstructured":"Acosta RK, Willkom M, Andreatta K, Liu H, Martin R, Parvangada A, et al. Switching to bictegravir\/emtricitabine\/tenofovir Alafenamide (B\/F\/TAF) from dolutegravir (DTG)\u2009+\u2009F\/TAF or DTG\u2009+\u2009F\/Tenofovir disoproxil fumarate (TDF) in the presence of Pre-existing NRTI resistance. J Acquir Immune Defic Syndr. 2020;85(3):363\u201371. https:\/\/doi.org\/10.1097\/QAI.0000000000002454.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"25","key":"789_CR25","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1056\/NEJMoa2210005","volume":"388","author":"LA Ombajo","year":"2023","unstructured":"Ombajo LA, Penner J, Nkuranga J, Mecha J, Mburu M, Odhiambo C, et al. Second-Line switch to dolutegravir for treatment of HIV infection. N Engl J Med. 2023;388(25):2349\u201359. https:\/\/doi.org\/10.1056\/NEJMoa2210005.","journal-title":"N Engl J Med"},{"issue":"1 Suppl","key":"789_CR26","first-page":"51","volume":"30","author":"LB Mulenga","year":"2022","unstructured":"Mulenga LB, Fwoloshi S, Mweemba A, Siwingwa M, Sivile S, Kampamba D, et al. Dolutegravir with recycled NRTIs is noninferior to PI-Based ART: VISEND trial. Top Antivir Med. 2022;30(1 Suppl):51\u20132.","journal-title":"Top Antivir Med"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00789-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-025-00789-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00789-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T08:30:44Z","timestamp":1758875444000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-025-00789-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["789"],"URL":"https:\/\/doi.org\/10.1186\/s12981-025-00789-7","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Using the Department of Health and Human Services regulations found at 45 CFR 46.104(d)(4), the central IRB (Advarra IRB, Advarra, 6100 Merriweather Drive, Suite 600, Columbia, Maryland, USA) determined that the research project was exempt from the IRB oversight. Individual identifying information was not accessed by the investigators during the study, therefore consent was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PS is a consultant for Gilead Sciences, ViiV Healthcare, and Merck. He received research grants from Gilead Sciences, Merck, and ViiV Healthcare. JR is an employee of Trio Health. MD, NPM and JG are employees of Gilead Sciences. SS serves on the Medical Advisory Board for Gilead Sciences and is a Speaker for Gilead Sciences. KM advises for ViiV Healthcare, Merck, and Gilead Sciences. He is on the speakers\u2019 bureau for ViiV Healthcare, Merck, and Gilead Sciences. He received research grants from ViiV Healthcare, Merck, and Gilead Sciences. MR is a consultant for ViiV Healthcare, Gilead Sciences, and Merck and received research funding from these companies. RE has received grants from Gilead Sciences and ViiV Healthcare, serves on the Advisory boards for Gilead Sciences and ViiV Healthcare, and is a speaker for Gilead Sciences. He is the Chairman of Trio Health Scientific Steering Committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}